WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN
26.10.2026 11:30:00 CET | Business Wire | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments.
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN
While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings.
Performance extends beyond sport and competition. It is how we move, recover, adapt, and continue doing what we love. WHOOP helps people better understand their bodies so they can make smarter choices across sport, health, and life.
Designed for changing states, Layer 2 brings SR_A’s distinct architectural language to garments that combine tactile materials, considered construction, and technical requirements. The collection uses nature's terrain as both inspiration and proving ground, creating pieces designed to perform across environments.
“I've always said our ambition with WHOOP is to create something that's either cool or invisible,” said Will Ahmed, Founder and CEO of WHOOP. “Our partnership with Samuel Ross pushes that philosophy to the next level. PROJECT TERRAIN reflects the respect we've always had for great design and our belief that the technology you wear every day should be something you love wearing.”
“PROJECT TERRAIN is an expression of intensity and resilience, designed for those who embrace exploration, discipline and the pursuit of performance,” said Samuel Ross MBE, Global Creative Director of WHOOP x SR_A. “Our second collection draws inspiration from the transition between dense urban environments and expansive rural landscapes, creating functional garments that adapt across all five zones of training. Combining exceptional technical fabrics, precision construction and refined silhouettes, the collection balances performance with everyday utility. At its core, PROJECT TERRAIN is about creating resilient, purposeful garments for those who push beyond their limits.”
PROJECT TERRAIN Layer 2 Collection
The limited-edition Layer 2 collection includes two new band designs for WHOOP 5.0 and WHOOP MG, alongside a range of men’s and women’s apparel, outerwear, and accessories. Products range from $60 to $650, with WHOOP bands priced at $99.
Collection Details
WHOOP 5.0 and WHOOP MG Bands
ATLAS BAND— $99/ €99 / £69
[Colors: Cinder, Volta]
Performance and Activewear
02 - NOMAD TECHNICAL PUFFER — $650/ €749 / £639
[Colors: Onyx, Solstice]
02 STRATA TECHNICAL JOGGER — $130/ €129/ £99
[Colors: Ash, Earth, Onyx]
02 -TERRAIN FITTED TEE - WOMEN — $100 / €99 / £69
[Colors: Onyx, Terra]
02 - TERRAIN FITTED TEE - MEN — $100 / €99 / £69
[Colors: Onyx, Terra]
02 - STRATA TECHNICAL SHORT — $110 / €119 / £89
[Colors: Ash, Earth, Onyx]
02 - SUMMIT SCULLY — $60 / €64 / £49
[Color: Onyx]
02 - FRAME PERFORMANCE BRA — $90 / €89 / £69
[Color: Terra]
02 - FRAME PERFORMANCE LEGGINGS — $130 / €129 / £99
[Color: Terra]
“As wearable technology becomes increasingly integrated into how we live, the opportunity lies in rethinking how and where it is worn. Following the sell-out of our debut PROJECT TERRAIN collection, Layer 2 builds on WHOOP’s Any-Wear™ technology to explore new sensor placements across technical garments, extending from performance apparel into outerwear and everyday wear. At SR_A, our thesis is to apply design thinking to the next evolution of wearable technology and changing ways of living, combining material innovation, functional utility and purposeful form to create products that move beyond conventional categories. PROJECT TERRAIN challenges conventional boundaries between technology, garment design and everyday life,” said Yi Ng, co-founder and CEO of SR_A.
PROJECT TERRAIN Layer 2 is now available at https://shop.whoop.com.
To view images of the collection, visit the digital press kit here.
About WHOOP
WHOOP delivers a wearable membership to help people live healthier, longer lives and unlock extraordinary potential. Through a powerful 24/7 wearable with a 14-day battery life, WHOOP provides intelligent health guidance across sleep, recovery, strain, fitness, and longevity. The health platform includes an FDA-cleared ECG, a Healthspan longevity feature, Blood Pressure Insights, and Advanced Labs blood biomarker analysis. Research shows that people who wear WHOOP daily log more than 90 additional minutes of exercise per week, get over two extra hours of sleep, and have 10% higher heart rate variability.
Trusted by millions of members worldwide including athletes, global leaders, military operators, executives, and artists, WHOOP has become a modern symbol of disciplined, intentional living. WHOOP was founded in 2012 and is headquartered in Boston. The company has raised more than $950 million in venture capital, ships to 56 countries, and operates in six languages. To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube.
About SR_A
SR_A is a garment atelier fortifying the body.
The atelier produces bespoke seasonal collections rooted in craft, innovation and utility, alongside distinct collaborations with industry leaders including LVMH group, Nike Inc & Apple Group.
Headquartered in London, the atelier was co-founded by Samuel Ross MBE and his longtime business partner, Yi Ng in 2019.
Well known for its considered ethos, rooted in the expression of architecture, cultural subversion, and deeply functional garments for living, SR_A’s study of serving the human body has led to several patent filings and global recognition awards across fashion and design.
SR_A's legacy retail partners include Dover Street Market & BIOTOP Japan.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261026029587/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 12:00:00 CET | Press release
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom